KRAS and neoplasm: In some malignant tumours such as lung adenocarcinoma, RIT1 mutations appear to be mutually exclusive with mutations in currently known driver genes such as KRAS and EGFR, which suggests that RIT1 may be an independent oncogenic factor in some tumours [17].